With supportive evidence provided by preclinical studies assessing the efficacy of DNA-PKcs inhibition for cancer treatment [42,43], we thus propose that therapeutic strategies that target the DNA-PKcs/cofilin2 interaction, and/or promote cytoskeleton stabilization, may be valuable to prevent or treat endotoxemia-related myocardial microvascular injury. The gene discussed is PRKDC; the disease is cancer.